Theradiag press release in response to the public takeover bid for Theradiag shares initiated by Biosynex
This press release has been prepared and is distributed pursuant to the provisions of Article 231-26 of the AMF General Regulations.
The draft takeover bid, the draft information memorandum and the draft memorandum in response (the “Draft Response Memorandum”) remain subject to review by the AMF.
If you wish to receive all of the company’s financial communications in real time, you can register directly by email at the following address: [email protected]